Sunshine Biopharma Company Leadership
| SBFM Stock | USD 2.28 0.05 2.24% |
Sunshine Biopharma employs about 44 people. The company is managed by 7 executives with a total tenure of roughly 42 years, averaging almost 6.0 years of service per executive, having 6.29 employees per reported executive. Analysis of Sunshine Biopharma's management performance can provide insight into the firm performance.
| Steve Slilaty Chairman Chairman, CEO and Pres |
Sunshine |
Sunshine Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.1075) % which means that it has lost $0.1075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1798) %, meaning that it created substantial loss on money invested by shareholders. Sunshine Biopharma's management efficiency ratios could be used to measure how well Sunshine Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Sunshine Biopharma Workforce Comparison
Sunshine Biopharma is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 11,650. Sunshine Biopharma adds roughly 44.0 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of (0.13) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.13. Sunshine Biopharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sunshine Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sunshine Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Sunshine Biopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Camille Sebaaly over a week ago Acquisition by Camille Sebaaly of 129468927 shares of Sunshine Biopharma subject to Rule 16b-3 | ||
Steve Slilaty over a month ago Disposition of 2591500 shares by Steve Slilaty of Sunshine Biopharma at 0.05 subject to Rule 16b-3 | ||
Michel Roy over two months ago Insider Trading | ||
Keller Andrew Mark over two months ago Disposition of tradable shares by Keller Andrew Mark of Sunshine Biopharma subject to Rule 16b-3 | ||
Camille Sebaaly over six months ago Acquisition by Camille Sebaaly of 14000000 shares of Sunshine Biopharma at 0.001 subject to Rule 16b-3 | ||
Camille Sebaaly over six months ago Acquisition by Camille Sebaaly of 26000000 shares of Sunshine Biopharma at 0.001 subject to Rule 16b-3 | ||
Abderrazzak Merzouki over a year ago Acquisition by Abderrazzak Merzouki of 27000000 shares of Sunshine Biopharma at 0.001 subject to Rule 16b-3 | ||
Steve Slilaty over a year ago Discretionary transaction by Steve Slilaty of 17000000 shares of Sunshine Biopharma subject to Rule 16b-3 |
Sunshine Biopharma Notable Stakeholders
A Sunshine Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sunshine Biopharma often face trade-offs trying to please all of them. Sunshine Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sunshine Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Steve Slilaty | Chairman, CEO and Pres | Profile | |
| Robert Ferreira | President Inc | Profile | |
| Abderrazzak Merzouki | COO and Director | Profile | |
| Camille Sebaaly | CFO, Principal Accounting Officer, Secretary and Director | Profile | |
| Malek Chamoun | Chief Officer | Profile | |
| Michel Roy | Chief Officer | Profile | |
| Marc Beaudoin | Chief Officer | Profile |
About Sunshine Biopharma Management Performance
The success or failure of an entity such as Sunshine Biopharma often depends on how effective the management is. Sunshine Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sunshine management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sunshine management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada. Sunshine Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.
Sunshine Biopharma Workforce Analysis
Traditionally, organizations such as Sunshine Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sunshine Biopharma within its industry.Sunshine Biopharma Manpower Efficiency
Return on Sunshine Biopharma Manpower
| Revenue Per Employee | 547.6K | |
| Revenue Per Executive | 3.4M | |
| Net Loss Per Employee | 102.4K | |
| Net Loss Per Executive | 643.7K | |
| Working Capital Per Employee | 439.5K | |
| Working Capital Per Executive | 2.8M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.